MedPath

CPAP vs ASV for Insomnia

Not Applicable
Completed
Conditions
Sleep-Disordered Breathing
Insomnia
Interventions
Device: AirCurve 10 ASV
Registration Number
NCT02365064
Lead Sponsor
ResMed
Brief Summary

The study will determine which of two different types of positive airway pressure (PAP therapy) modes are more effective in reducing sleep breathing events in chronic insomnia patients and in decreasing insomnia severity.

Detailed Description

Patients presenting to the sleep clinic with a primary complaint of insomnia will be potential participants for this study. Following diagnostic polysomnography (PSG) testing, insomnia patients diagnosed with SDB and meeting inclusion criteria will be randomized to a PAP treatment arm, CPAP or ASV. Participants will complete titration studies with their assigned PAP mode and attend clinical follow-up appointments over a 14-16 week timeframe. Titration PSG studies will assess PAP pressure needs to ensure that patients are receiving optimal therapy at all times during this study. PAP adaptation barriers will be addressed as they arise during the study, because it is important that participants are able to use PAP therapy nightly during participation in this protocol. Baseline scores on insomnia severity, sleep quality, subjective insomnia parameters, sleep related impairment, and quality of life will be compared to outcome measures at the 4 month mark. Pre-treatment and post-treatment objective improvements on sleep studies will also be compared including sleep breathing indices, sleep consolidation indices, and objective data download information.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • Primary complaint of insomnia when presenting at clinic
  • Diagnosis of moderate to severe insomnia through the Insomnia Severity Index (ISI) with a score ≥ 15
  • Meet diagnostic criteria of Insomnia Disorder (per American Academy of Sleep Medicine)
  • Diagnosis of SDB, either OSA as determined by an AHI ≥ 5 events/hour or UARS with a RDI ≥ 15 events/hour and AHI < 5 events/hour
  • Naïve to treatment for sleep-disordered breathing (SDB), including CPAP, APAP, ASV; mandibular repositioning devices (MRDs), and any other nasal or oral therapy with a primary indication of treating SDB
  • Able to fully understand study information in English and sign informed consent
Exclusion Criteria
  • Primary complaint of sleep-disordered breathing or issues with apneas during sleep
  • Severe respiratory disorder or severe sleep disorder such as restless leg syndrome (RLS), idiopathic hypersomnia, or narcolepsy
  • BMI > 30 kg/m2
  • Epworth Sleepiness Scale (ESS) score ≥ 10
  • Frequent napping behavior, such as a few times a week or more
  • Anticipated changes to start or stop sedative or psychotropic medications during the course of the trial
  • Medical history of congestive heart failure (CHF) or other potentially unstable cardiac disease as well as chronic lung diseases or other debilitating medical conditions that manifest as more prominent in the patient's health compared to their sleep complaints
  • Daily use of opiate medications
  • Known contraindications to PAP therapy as listed in the indication for use
  • Requires a CPAP (fixed) pressure > 20 cm H2O
  • Inability to comply with study procedures

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Continuous Positive Airway PressureAirCurve 10 ASVContinuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
Adaptive Servo-VentilationAirCurve 10 ASVAdaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
Primary Outcome Measures
NameTimeMethod
Insomnia Severity IndexBaseline and 4 months

Change in insomnia severity from baseline to 4 months as measured by subjective questionnaire. The Insomnia Severity Index has seven questions. The seven answers are added up for a total score. Scores range from 0 - 28. A higher score indicates a more severe degree of insomnia.

Secondary Outcome Measures
NameTimeMethod
Global Morning Rating4 months

Change in subjective rating from baseline to 4 months based on a 0-100% scale. Lower scores equal a more positive experience

Sleep Onset Latency4 months

Change in from baseline to 4 months in sleep onset time (minutes)

Sleep Quality RatingBaseline and 4 months

8 point Likert scale for change in subjective sleep quality from baseline to 4 months. Lower scores indicated more positive sleep quality. A score 0 indicates excellent sleep quality, and a score of 7 indicates very poor sleep quality

Wake After Sleep Onset (WASO)4 months

Change from baseline to 4 months for WASO in minutes

Sleep Efficiency4 months

Change from baseline to 4 months in sleep efficiency (total sleep time/time in bed)

Trial Locations

Locations (1)

Maimonides Sleep Arts & Sciences

🇺🇸

Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath